This is the first time the Agency has authorized the Phase 3 clinical evaluation in the U.S of a microbiota-based live biotherapeutic based on a pooling technology
The New State-of-Art OligoPilot 2000 solid-phase synthesizer adds cGMP manufacturing capacity to support and accelerate clinical and commercial oligonucleotide programs.
The acquisition is a crucial step in LTS' strategy to broaden its portfolio of drug delivery platforms.
Aji Bio-Pharma has six fill finish lines located in San Diego, including a new line
The acquisition would be by way of a share purchase agreement dated Dec. 26, 2022.
Bayer reported the highest market capitalization growth of 23.1% during Q1 2023
Several late-stage pipeline products have the potential to address some of these unmet needs
Digitization has unleashed a flood of data that presents a huge opportunity but is also overwhelming clinicians, nurses, and administrators
The data highlight the three drug candidates' potential for clinical development and promising synergistic utilities in new indications
WuXi Bio provided technical services, based on the companies' versatile integrated service platforms, to support various manufacturing and process development activities of these ADC product candidates.
Subscribe To Our Newsletter & Stay Updated
